Finding Genius Podcast Rewiring Recovery: Advancing Nervous System Repair With NervGen’s Mike Kelly
Apr 8, 2025
Mike Kelly, President and CEO of NervGen, brings over 30 years of pharmaceutical expertise to the table. He discusses groundbreaking advancements in nervous system repair, particularly regarding spinal cord injuries. The conversation dives into clinical trials for their promising drug candidate, NVG-291, and how new protocols might change the landscape of recovery. Mike also highlights the importance of biomarker analysis in indicating breakthroughs, and shares insights on the journey to FDA approval, emphasizing the impact on real-world treatment.
AI Snips
Chapters
Transcript
Episode notes
Mike Kelly's Career Path
- Mike Kelly's career began at Tap Pharmaceuticals, spanning commercial roles and startups.
- His experience includes Byropharma, Guilford, Pure Startups, and AdaptPharma, where he launched Narcan nasal spray.
NervGen's Technology and Focus
- NervGen's technology, based on Dr. Jerry Silver's research, targets molecules inhibiting nervous system repair.
- NVG-291, their lead product, is in clinical trials for spinal cord injury, with preclinical studies for NVG-300 in stroke, ALS, and SCI.
Clinical Trial Design
- The phase 1B2A trial includes two groups: one to ten years post-injury and 20 to 90 days post-injury.
- The trial measures connectivity between the brain and limbs, as well as functional improvements like walking and motor skills.